Use of recombinant allergens and antigens in clinical diagnosis (Q12379): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 1 language: translated_label) |
(Removed claim: summary (P836): The project involves industrial research and experimental development in the area of diagnosis in vitro, specifically to use recombinant allergens and antigens in the form of prototype BAT and ELISA kits for qualitative diagnosis and therapy monitoring for patients and selected bacterial infections. The resulting high-tech products get off the parameters of the world’s peak or go beyond the technical parameters of the known solutions and will...) |
||
| Property / summary | |||
| Property / summary: The project involves industrial research and experimental development in the area of diagnosis in vitro, specifically to use recombinant allergens and antigens in the form of prototype BAT and ELISA kits for qualitative diagnosis and therapy monitoring for patients and selected bacterial infections. The resulting high-tech products get off the parameters of the world’s peak or go beyond the technical parameters of the known solutions and will be displayed on the European and world scene. a. (English) / rank | |||
Revision as of 15:29, 22 October 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Use of recombinant allergens and antigens in clinical diagnosis |
Project in Czech Republic financed by DG Regio |
Statements
15,323,532.49 Czech koruna
0 references
24,835,547.0 Czech koruna
0 references
61.7 percent
0 references
30 June 2022
0 references
EXBIO Praha, a.s.
0 references
49°59'0.49"N, 14°30'9.11"E
0 references
25250
0 references
Předmětem projektu je průmyslový výzkum a experimentální vývoj zaměřený na oblast diagnostik in vitro, konkrétně na využití rekombinantních alergenů a antigenů v podobě prototypů BAT testů a ELISA souprav pro kvalitativní diagnostiku a monitoring terapie alergologických reakcí pacientů a vybraných bakteriálních infekcí. Výsledné high-tech produkty se vyrovnají parametrům světové špičky, resp. překračují technické parametry známých řešení a budou uvedeny na evropský a světový trh. a. (Czech)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_176/0015521
0 references